News | February 02, 2015

Biosensors Enters Into Distribution Agreement with Veryan for BioMimics 3D Stent

Stent mimics natural geometry of the human vascular system

Stents, BioMimics 3D, Veryan Medical, Biosensors International Group

Image courtesy of Veryan Medical

February 2, 2015 — Biosensors International Group has announced a distribution agreement with Veryan Medical Ltd. for BioMimics 3D, a nitinol stent with three-dimensional helical geometry designed for use in the superficial femoral artery.  The agreement covers certain international markets, but excludes the United States and Japan.

The BioMimics 3D stent incorporates Veryan’s patented 3-D helical technology, an advanced stent design that promotes natural swirling blood flow to elevate wall shear stress, which has been shown to reduce neointimal hyperplasia. The 3-D advanced design has also been shown to improve the biomechanical performance of the stent when implanted in the femoropopliteal artery, mitigating the risk of stent fracture and vessel kinking.  An estimated 200,000 endovascular femoropopliteal procedures are performed each year in the EU alone.

Two-year data from the Mimics study have confirmed that BioMimics 3D provides significant improvement in long-term patency compared to a straight nitinol control stent in patients undergoing femoropopliteal artery intervention. The data indicates a correlation between primary patency and stent curvature. In addition, a 12-month Landmark analysis reinforces the longer term benefit of Veryan’s helical stent technology and shows a statistically significant improvement in the Kaplan-Meier estimate of survival from clinically-driven TLR through 24 months, compared to the control stent.

Veryan received CE Mark approval for the BioMimics 3D stent in September 2012. Biosensors expects to commence active promotion of BioMimics 3D in Q1 2015.

For more information:,



Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Overlay Init